As we enter the season of thankfulness and giving, it is with gratitude and excitement that we introduce the 12 incredible individuals who have been selected...
Introducing TCF’s 2025 Boston Marathon team!
read more
News
Patients and Practitioners as Partners: 2024 Rare Cancer Day Webinar
On September 30, TargetCancer Foundation was pleased to host a Lunch and Learn Webinar in honor of Rare Cancer Day. Dr. Mina Nikanjam, an oncologist at...
Making Rare Cancer Day A Reality
This reflection was written by: Jim Palma, Chief Executive Officer Like many people in the rare cancer advocacy world, I entered my own advocacy work...
Connecting the Dots: Two Months at TCF
This reflection was written by: Hetal Vig, MS, MGC, Director of Research and Clinical Engagement In the words of Steve Jobs, “You can’t connect the dots...
Remembering at 15 years
Dear Friends, This past spring, TCF celebrated 15 years of amazing achievement in rare cancer research. We have so much to be proud of, and I am. But today is...
Welcome, Hetal!
A Message from TargetCancer Foundation President Kristen Palma: When TCF was founded in 2009, we started around the kitchen table. It was Paul, myself and my...
Highlighting Our History
In honor of our 15th anniversary, TCF created videos that were featured at the TargetCancer Foundation Gala in April. These three videos each focus on a...
Reflections on 15 Years of TargetCancer Foundation
This milestone of TargetCancer Foundation’s 15 year anniversary has stopped me in my tracks. It is a long time to be doing this work and a long time to grieve...
2023: An Impactful Year In Review
RESEARCH → TCF-001 TRACK Our fully remote, decentralized precision medicine clinical trial has enrolled 157 patients with 40 rare cancers from 41 states,...
Thank you to our Community Fundraisers!
February is Cholangiocarcinoma Awareness Month. We are proud to highlight the many efforts from TCF community members who are working to bring attention to...
TCF Executive Director Jim Palma to Receive the 2022 Ruesch Center Luminary Award in GI Cancers
We are incredibly proud to announce that our Executive Director Jim Palma has been named a Ruesch Center 2022 Luminary Awards in GI Cancer recipient! The...
A Reflection of Purpose After 13 years: Remembering Our Founder
Written by Kristen Palma, TargetCancer Foundation President Each year, as I sit down to write this note, I wonder what more I can say. It has been 13...
Introducing Giselle Mota, our Newest Volunteer!
We are pleased to introduce you to TargetCancer Foundation's newest volunteer, Giselle Mota. Originally from Los Angeles, CA, Giselle currently resides in...
Promising New Cholangiocarcinoma Treatment Findings
An exciting paper was recently published in Cancer Discovery highlighting the promise of the recently FDA approved FGFR inhibitor drugs for an even broader...
Breaking New Ground: FDA Approves Pemazyre, the First Targeted Therapy for Cholangiocarcinoma
In the midst of such a challenging time, I wanted to take a moment to share some very positive and exciting news with you. Late last week, the FDA granted...